Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
Pharmabiz

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
Investing.com Australia

Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe

Wolfe upgraded Merck to Outperform from Peer Perform and set a $135 price target, saying the drugmaker is approaching a new ...

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Nasdaq

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...